Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Kumar, Princy ^a   DeJesus, Edwin ^b   Huhn, Gregory ^c   Sloan, Louis ^d   Small, Catherine Butkus ^e   Edelstein, Howard ^f   Felizarta, Franco ^g   Hao, Ritche ^h   Ross, Lisa ⁱ   Stancil, Britt ^j   Pappa, Keith ^j   Ha, Belinda ⁱ  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Ruth M Rothstein CORE Center   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f ALAMEDA COUNTY MEDICAL CENTER   (United States)

^g Private Practice   (United States)

^h Chase Brexton Health Services   (United States)

ⁱ VIIV HEALTHCARE   (United States)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Abacavir; Cardiovascular biomarker; Efavirenz; Fosamprenavir; HIV; Lamivudine; Minority; Ritonavir; Underrepresented

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; EFAVIRENZ; FIBRINOGEN; FOSAMPRENAVIR; INTERLEUKIN 6; LEXIVIA; PLASMINOGEN; RITONAVIR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA;

ACUTE PANCREATITIS; ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ARREST; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; PROSPECTIVE STUDY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARBAMATES; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHATES; PLASMINOGEN; PROSPECTIVE STUDIES; RITONAVIR; SULFONAMIDES; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84878666206     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-269     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention Leading causes of death [http://www.cdc.gov/nchs/fastats/lcod.htm/], Centers for Disease Control and Prevention.
2. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Gorozy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shilpak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P, OAR Working Group on HIV and Aging HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012, 60:S1-S18. OAR Working Group on HIV and Aging.
3. Fichtenbaum CJ. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?. Curr HIV/AIDS Rep 2010, 7:92-98. 10.1007/s11904-010-0045-5, 20425563.
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007, 92:2506-2512. 10.1210/jc.2006-2190, 2763385, 17456578.
5. Schouten J, AGEhIV Study Group Comorbidity and ageing with HIV: a prospective comparative cohort study 2012, Washington, DC: Program and abstracts of the XIX International AIDS Conference, Oral presentation THAB0205, AGEhIV Study Group.
6. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, Havlir DV, Hsue PY. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012, 59:1891-1896. 10.1016/j.jacc.2012.02.024, 3356565, 22595409.
7. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. European Heart J 2011, 32:945-951.
8. Thomas AJ, Eberly LE, Davey Smith G, Neaton JD, Stamler J. Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health 2005, 95:1417-1423. Epub 2005 Jul 7, 10.2105/AJPH.2004.048165, 1449375, 16006418.
9. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009, 10:79-87. 10.1111/j.1468-1293.2008.00661.x, 19200170.
10. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011, 11:40. 10.1186/1471-2334-11-40, 3042932, 21294867.
11. Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kurtizkes DR, Glesby MJ, AIDS Clinical Trials Group A5095 Study Team Change in high-sensitivity C-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2011, 27:461-468. 10.1089/aid.2010.0154, 3083724, 20863238, AIDS Clinical Trials Group A5095 Study Team.
12. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Schaefer MS, HEAT study team Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009, 23:1547-1556. 10.1097/QAD.0b013e32832cbcc2, 19542866, HEAT study team.
13. Palella FJ, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, Tracy RP, Elion R. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010, 24:1567-1665.
14. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012, 26:1371-1385. 10.1097/QAD.0b013e328354f4fb, 3560932, 22546988.
15. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, AIDS Clinical Trials Group Study A5202 Study Team Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med 2011, 154:445-456. 10.7326/0003-4819-154-7-201104050-00316, 3430716, 21320923, AIDS Clinical Trials Group Study A5202 Study Team.
16. Tien PC, Choi AI, Zolopa AR, Benson C, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010, 55:316-322. 10.1097/QAI.0b013e3181e66216, 2955817, 20581689.
17. Wegner S, Vahey M, Dolan M, Wallace M, Aronson N, Barile A, Emmons W, Frazier S, Stephan K, Nau M, Piscitelli S, Harrigan R, Larder B. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy 2002, Seattle, Washington: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Abstract 428-W.
18. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group study. J Infect Dis 2005, 192:1931-1942. 10.1086/497610, 16267764.
19. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006, 296:769-781. 10.1001/jama.296.7.769, 16905783, AIDS Clinical Trials Group (ACTG) A5095 Study Team.
20. Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA, ESS40002 Study Team A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006, 7:85-98. 10.1111/j.1468-1293.2006.00346.x, 16420253, ESS40002 Study Team.
21. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008, 22:1709-1717. 10.1097/QAD.0b013e32830163ad, 18753940.
22. Smith K, Tierney C, Daar E, Mollan K, Budhathoki C, Sax P, Katzenstein D, Godfrey C, Fischl M, Collier A, ACTG A5202 Study Team Association of race/ethnicity and sex on outcomes in ACTG study A5202 2011, Boston, Massachusetts: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections, Abstract 536, ACTG A5202 Study Team.
23. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD, DAD Study Group Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. DAD Study Group.
24. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD, D:A:D Study Group Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426. 2688660, 18387667, D:A:D Study Group.
25. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010, 170:1228-1238. 10.1001/archinternmed.2010.197, 20660842, Clinical Epidemiology Group of the French Hospital Database on HIV.
26. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011, 53:84-91. 10.1093/cid/cir269, 21653308.
27. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011, 25:1993-2004. 10.1097/QAD.0b013e328349c6ee, 21716077.
28. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012, 61:441-447. 10.1097/QAI.0b013e31826f993c, 22932321.
29. Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008, 22:1673-1675. 10.1097/QAD.0b013e32830719aa, 18670229.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 26 April 2013. Page C-22, Panel on Antiretroviral Guidelines for Adults and Adolescents.
31. Fichtenbaum C. Inflammatory markers associated with coronary heart disease in persons with HIV infection. Curr Infect Dis Rep 2011, 13:94-101. 10.1007/s11908-010-0153-9, 3077066, 21308460.
32. Baker JV, Neuhaus J, Duprez D, Kuller LW, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD, INSIGHT SMART Study Group Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011, 56:36-43. 10.1097/QAI.0b013e3181f7f61a, 3005856, 20930640, INSIGHT SMART Study Group.
33. Arildsen H, Sorensen K, Ingerslev J, Ostergaard L, Laursen A. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2012, epub prior to print.
34. Kaplan RC, Landay AL, Hodis HN, Gange SJ, Norris PJ, Young M, Anastos K, Tien PC, Xue X, Lazar J, Parrinello CM, Benning L, Tracy RP. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012, 60:359-368. 10.1097/QAI.0b013e31825b03be, 22592585.
35. Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD, INSIGHT SMART Study Group HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012, 60:128-134. 10.1097/QAI.0b013e318252f99f, 3360839, 22421746, INSIGHT SMART Study Group.
36. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH, ACTG 5152s Study Team Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008, 52:569-576. 10.1016/j.jacc.2008.04.049, 2603599, 18687253, ACTG 5152s Study Team.
37. Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH, SABAR Study Team Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 2010, 24:885-890. 10.1097/QAD.0b013e3283352ed5, 19952712, SABAR Study Team.